This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apricus Biosciences Announces Poster Presentation Of Vitaros(R) Data In Men Previously Unresponsive To PDE-5 Inhibitors At American Urological Association Annual Meeting

Stocks in this article: APRI

SAN DIEGO, May 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( announced today that John P. Mulhall, MD, Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan-Kettering Cancer Center, will present results from an analysis of existing Phase 3 data for Vitaros®, the Company's lead product candidate for the treatment of erectile dysfunction (ED), at the American Urological Association Annual Meeting which is taking place May 4-8, 2013 in San Diego, CA.

The abstract titled, "Vitaros ® Efficacy and Safety in Viagra ® Non-Responders with Longer Term Use," will be presented as a moderated poster (#1519) during a session titled "Sexual Function/Dysfunction/Andrology: Medical and Non-Surgical Therapy," taking place Tuesday, May 7, 2013 from 8-10 a.m. local time. Dr. Mulhall will give a short oral presentation, which will then be followed by a question and answer period.

This analysis evaluated the safety and efficacy of Vitaros ® after 12 weeks, and longer term use, in men previously unresponsive to phosphodiesterase type 5 (PDE-5) inhibitors, such as Viagra ® (n=325). Results showed that 200mcg and 300mcg doses of Vitaros® improved erections in this population and adverse events (AE) were mild to moderate, similar to those seen in the control group, and decreased with repeated exposure.

"PDE-5 inhibitors, while effective, address only a portion of the ED patient population. In the current treatment landscape, this leaves a large population of unresponsive or contraindicated patients with few or no alternatives," said Dr. John Mulhall, lead author and Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan-Kettering Cancer Center. "Vitaros ® utilizes a novel mechanism of action that has demonstrated successful ED therapy without the side effects associated with current products, making it an effective and practical option for these patients."

Dr. Mulhall is also an Associate Editor for the Journal of Sexual Medicine and past President of the Sexual Medicine Society of North America.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs